Abrégé

The present invention provides combinations comprising (a) a compound of formula (I) wherein M(III) is an ion selected from Al, Fe and Ga; or a pharmaceutically acceptable salt thereof, and (b) a triazole-based antifungal agent or a pharmaceutically acceptable salt thereof, as well as methods of using the combinations in the prevention and treatment of fungal infections.

Classes IPC  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
• A61P 31/10 - Antifongiques

Abrégé

Described herein are heterocycle substituted pyridine derivative antifungal agents and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.

Classes IPC  ?

• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• A61P 31/10 - Antifongiques
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 471/04 - Systèmes condensés en ortho
• C07F 9/6558 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant au moins deux hétérocycles différents ou différemment substitués ni condensés entre eux ni condensés avec un carbocycle commun ou un système carbocyclique commun

Abrégé

The present invention provides processes for preparing a compound of formula I and pharmaceutically acceptable salts thereof, The present invention provides processes for preparing a compound of formula I and pharmaceutically acceptable salts thereof, The present invention provides processes for preparing a compound of formula I and pharmaceutically acceptable salts thereof, comprising deprotecting a compound of formula II The present invention provides processes for preparing a compound of formula I and pharmaceutically acceptable salts thereof, comprising deprotecting a compound of formula II The present invention provides processes for preparing a compound of formula I and pharmaceutically acceptable salts thereof, comprising deprotecting a compound of formula II wherein each R3 independently represents a tertiary alkyl group, preferably wherein each R3 is tertiary butyl. The invention also provides intermediates useful for preparing compounds of formula I and processes for preparing these intermediates. Additionally the invention provides polymorphic forms of the dichloride salt of the compound of formula I and their use in the treatment of proliferative disorders.

Classes IPC  ?

• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07C 269/06 - Préparation de dérivés d'acide carbamique, c.-à-d. de composés contenant l'un des groupes l'atome d'azote ne faisant pas partie de groupes nitro ou nitroso par des réactions n'impliquant pas la formation de groupes carbamate
• C07C 271/06 - Esters des acides carbamiques

Produits et services

Pharmaceutical preparations and substances for the treatment of infectious diseases, for the treatment of dermatological disorders, for the treatment of oncological diseases, for the treatment of gastrointestinal diseases, for the treatment of neurological diseases, for the treatment of cardiovascular diseases, and for the treatment of gynecological diseases

Abrégé

The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.

Classes IPC  ?

• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A01N 37/46 - Dérivés N-acylés
• A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
• A61P 31/04 - Agents antibactériens
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides

Produits et services

chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions and for the treatment of infections and diseases; chemical substances for use in research and development of pharmaceuticals for the treatment of dermatological conditions and for the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents, other than for medical or veterinary purposes diagnostic reagents for medical or veterinary purposes; pharmaceutical and veterinary products and preparations for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; pharmaceutical and veterinary products and preparations for the treatment and prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of oncology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of neurology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of urology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of hematology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of allergy; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of immunology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of anesthesiology; pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; diagnostic preparations for medical purposes; clinical medical reagents Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations

Abrégé

The present invention provides a blister-packaged No. 3 capsule preparation containing isavuconazonium sulfate, which has excellent physical properties. The preparation satisfies the following conditions (1) to (4): (1) the capsule used in the capsule preparation is Capsule Standard No. 3; (2) the major axis of a pocket containing the capsule preparation is 150 to 200% of the total length of 15.9 mm; (3) the minor axis of the pocket containing the capsule preparation is 295 to 345% of the outer diameter of 5.8 mm; and (4) the height of the pocket containing the capsule preparation is 100 to 150% of the outer diameter of 5.8 mm.

Classes IPC  ?

• B65D 75/32 - Objets ou matériaux enveloppés entre deux feuilles ou flans opposés à bords réunis, p. ex. par adhésifs à pression, pliage, thermosoudage ou soudage une ou les deux feuilles ou flans étant renfoncés pour épouser la forme du contenu
• B65D 81/26 - Adaptations pour empêcher la détérioration ou l'altération du contenuApplications au réceptacle ou au matériau d'emballage d'agents de conservation des aliments, de fongicides, d'insecticides ou de produits repoussant les animaux avec dispositifs pour évacuer ou absorber les fluides, p. ex. s'écoulant du contenuEmploi de produits empêchant la corrosion ou de dessiccateurs

Abrégé

The present invention provides methods of treating a S. aureus bloodstream infection (bacteremia) to a patient in need thereof, the method comprising administering ceftobiprole as ceftobiprole miedocaril to the patient at a dosage corresponding to 500 mg of ceffobiprole every 6 hours on days 1 to 8 and 500 mg every 8 hours on days 9 onwards.

Classes IPC  ?

• A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention provides methods of treating a S. aureus bloodstream infection (bacteremia) to a patient in need thereof, the method comprising administering ceftobiprole as ceftobiprole medocaril to the patient at a dosage corresponding to 500 mg of ceftobiprole every 6 hours on days 1 to 8 and 500 mg every 8 hours on days 9 onwards.

Classes IPC  ?

• A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine

Abrégé

The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), [X3]t—[X2]S—X1—P1—P2—P3—P4—P5—P6—P7—P8—P9—P10—P11—P12—P13—P14—P15—P16 and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61P 31/04 - Agents antibactériens
• A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges

Abrégé

Provided herein are compositions and methods of use thereof for the treatment of fungal infections and diseases.

Classes IPC  ?

• A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61P 31/10 - Antifongiques
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

22- may be replaced by -N(R3)- or -O- and wherein Y may be substituted by one -OH on a carbon atom that is not bound to an oxygen atom or a nitrogen atom, and R2 and R3 are as defined in the claims; as well as methods of using the compounds to treat neoplastic diseases, in particular cancer.

Classes IPC  ?

• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61P 35/00 - Agents anticancéreux

Produits et services

Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions and for the treatment of infections and diseases; chemical substances for use in research and development of pharmaceuticals for the treatment of dermatological conditions and for the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of allergies; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of anesthesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; diagnostic preparations for medical clinical purposes; clinical medical reagents; all of the aforesaid for prescription only Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations

Abrégé

The provision of an intravenous drip infusion set containing as an active ingredient 200 mg isavuconazole or prodrug thereof, calculated as isavuconazole, per administered dose, and having excellent filtration performance. The provision of at least: an infusion agent comprising isavuconazole or prodrug thereof, a bottle needle, a drip tube, a clamp, an air-vented infusion filter and an infusion tube, wherein said infusion tube is a tube that connects said bottle needle, said drip tube, said air-vented infusion filter and said venous needle, and the hydrophilic filter membrane provided inside said air-vented infusion filter is a polysulfone membrane or a Posidyne membrane.

Classes IPC  ?

• A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
• A61M 5/165 - Accessoires de filtrage, p. ex. filtres pour le sang, pour les liquides de perfusion
• A61K 31/4196 - 1,2,4-Triazoles
• A61P 31/10 - Antifongiques

Abrégé

Described herein is the use of compound 1, an antifungal agent with a novel mechanism of action, in the treatment of fungal infections.

Classes IPC  ?

• A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
• A61P 31/10 - Antifongiques

Abrégé

Described herein are heterocycle substituted pyridine derivative antifungal agents and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.

Classes IPC  ?

• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• A61P 31/10 - Antifongiques
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 471/04 - Systèmes condensés en ortho
• C07F 9/6558 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant au moins deux hétérocycles différents ou différemment substitués ni condensés entre eux ni condensés avec un carbocycle commun ou un système carbocyclique commun

Abrégé

The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 31/02 - Antiseptiques locaux
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Produits et services

Human pharmaceutical preparations, namely, anti-infectives

Abrégé

The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 31/04 - Agents antibactériens
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau

Abrégé

The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), [X3]t-[X2]S-X1-P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.

Classes IPC  ?

• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 31/02 - Antiseptiques locaux
• C07K 1/00 - Procédés généraux de préparation de peptides
• C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau

Produits et services

Human pharmaceutical preparations, namely, anti-infectives

Abrégé

Provided herein are compositions and methods of use thereof for the treatment of fungal infections and diseases.

Classes IPC  ?

• A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/107 - Émulsions
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 9/10 - DispersionsÉmulsions
• A61K 9/50 - Microcapsules
• A61K 9/08 - Solutions
• A61K 47/02 - Composés inorganiques
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61P 31/10 - Antifongiques
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 38/12 - Peptides cycliques
• A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 9/51 - Nanocapsules

Abrégé

Described herein are pyridine derivatives substituted by heterocycle and amino groups and pharmaceutical compositions comprising said compounds. The disclosed compounds are antifungal agents. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.

Classes IPC  ?

• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61P 31/10 - Antifongiques
• A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
• A61K 31/4174 - Arylalkylimidazoles, p. ex. oxymétazoline, naphazoline, miconazole
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
• A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
• A61K 38/12 - Peptides cycliques
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07H 15/26 - Radicaux acycliques ou carbocycliques substitués par des hétérocycles

Produits et services

Pharmaceutical preparations and substances for the treatment of infectious diseases, dermatological disorders, oncological diseases, gastrointestinal diseases, neurological diseases, cardiovascular diseases, gynecological diseases, and autoimmune diseases

Produits et services

Pharmaceutical products and preparations for human use for the treatment and prevention of cancer; pharmaceutical products and preparations for the treatment of cancer

Produits et services

Pharmaceutical products and preparations for human use for the treatment and prevention of cancer; pharmaceutical products and preparations for the treatment of cancer

Produits et services

Pharmaceutical products and preparations for human use for the treatment and prevention of cancer; pharmaceutical products and preparations for the treatment of cancer

Produits et services

Pharmaceutical preparations and substances for the treatment of infectious diseases, for the treatment of dermatological disorders, for the treatment of oncological diseases, for the treatment of gastrointestinal diseases, for the treatment of neurological diseases, for the treatment of cardiovascular diseases, and for the treatment of gynecological diseases

Produits et services

Pharmaceutical preparations and substances for human use for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer

Produits et services

(1) Produits et préparations pharmaceutiques à usage humain pour le traitement et la prévention du cancer, de la craniosynostose, de l'achondroplasie et des tumeurs à cellules géantes ténosynoviales ; produits et préparations pharmaceutiques pour le traitement du cancer.

Produits et services

(1) Produits et préparations pharmaceutiques à usage humain pour le traitement et la prévention du cancer, de la craniosynostose, de l'achondroplasie et des tumeurs à cellules géantes ténosynoviales ; produits et préparations pharmaceutiques pour le traitement du cancer.

Produits et services

(1) Produits et préparations pharmaceutiques à usage humain pour le traitement et la prévention du cancer, de la craniosynostose, de l'achondroplasie et des tumeurs à cellules géantes ténosynoviales ; produits et préparations pharmaceutiques pour le traitement du cancer.

Produits et services

(1) Produits et préparations pharmaceutiques à usage humain pour le traitement et la prévention du cancer, de la craniosynostose, de l'achondroplasie et des tumeurs à cellules géantes ténosynoviales ; produits et préparations pharmaceutiques pour le traitement du cancer.

Produits et services

Pharmaceutical products and preparations for human use for the treatment and prevention of cancer, craniosynostosis, achondroplasia, and tenosynovial giant cell tumors; pharmaceutical products and preparations for the treatment of cancer

Produits et services

Pharmaceutical products and preparations for human use for the treatment and prevention of cancer, craniosynostosis, achondroplasia, and tenosynovial giant cell tumors; pharmaceutical products and preparations for the treatment of cancer

Produits et services

Pharmaceutical products and preparations for human use for the treatment and prevention of cancer, craniosynostosis, achondroplasia, and tenosynovial giant cell tumors; pharmaceutical products and preparations for the treatment of cancer

Produits et services

Pharmaceutical products and preparations for human use for the treatment and prevention of cancer, craniosynostosis, achondroplasia, and tenosynovial giant cell tumors; pharmaceutical products and preparations for the treatment of cancer

Produits et services

(1) Pharmaceutical preparations, namely, anti-infectives, antibacterials, antifungals, antiparasitics, antivirals, anti-inflammatories, anticonvulsants, anticoagulants, antihypertensives, antineoplastics, immuno suppressants; and pharmaceutical preparations for the prevention or treatment of dermatological diseases and disorders, namely, dermatitis, eczema, lesions, hyperkeratosis, rosaceae, psoriasis, acne, wounds, wrinkles and scars.

Produits et services

(1) Pharmaceutical preparations, namely, anti-infectives, antibacterials, antifungals, antiparasitics, antivirals, anti-inflammatories, anticonvulsants, anticoagulants, antihypertensives, antineoplastics, immuno suppressants; and pharmaceutical preparations for the prevention or treatment of dermatological diseases and disorders, namely, dermatitis, eczema, lesions, hyperkeratosis, rosaceae, psoriasis, acne, wounds, wrinkles and scars.

Produits et services

(1) Pharmaceutical preparations and substances, namely antifungals

Produits et services

Pharmaceutical products and preparations for the treatment and prevention of infections caused by bacteria

Produits et services

Pharmaceutical preparations and substances, namely anti-fungicides.

Produits et services

Pharmaceutical preparations and substances, namely anti-fungicides.

Produits et services

(1) Human pharmaceuticals, namely, anti-infectives.

Produits et services

(1) Pharmaceutical preparations and substances, namely, antifungals.

Produits et services

(1) Pharmaceutical preparations and substances, namely antifungals.

Produits et services

Pharmaceutical preparations and substances, namely antifungals.

Produits et services

(1) Pharmaceutical preparations for human use, namely anti-infectives.

Produits et services

Pharmaceutical preparations for human use, namely anti-infectives.

Produits et services

Pharmaceutical preparations for human use.

Produits et services

Pharmaceutical preparations for human use, namely anti-infectives.

Produits et services

Pharmaceutical products and substances.